Niklas Mattsson

Banner image with text: 'Stay informed with the latest IP news' and the following words listed: Insights, Interviews, Webinars.

Breast cancer gene patents once again found valid by US appeals court

By Niklas Mattsson | Posted on August 23, 2012

In the “Myriad case” an ongoing legal battle with many twists and turns, the Court of Appeals for the Federal Circuit, CAFC, has decided to once again uphold patent claims covering isolated human genes BRCA1 and BRCA2, owned at least partly by Myriad Genetics Inc in Utah, USA. The patent claims were initially invalidated in...

Tags: gene patents, USA

Focus on China

By Niklas Mattsson | Posted on November 18, 2011

The fact that China is growing in importance is well known. To Awapatent, this growth is visible in our day-to-day work, both from the questions we get about IP in China from our European clients, and from the growing demand for our services as a European firm for Chinese clients. Naturally, we make it a...

Tags: china, IP, Patent

Supplementary protection for combination products heading for setback at the CJ of the EU

By Niklas Mattsson | Posted on July 14, 2011

Supplementary protection for combination products heading for setback at the Court of Justice of the EU On 13 July 2011, the opinion of the Advocate General (AG) was released in the consolidated cases C-322/10 and C-422/10, “Medeva” and “Georgetown” respectively, concerning supplementary protection certificates (SPCs) for combination vaccines. In her opinion, the AG recommends the...

Tags: CJ, EU, Medication, SPC

Most comprehensive patent reform in almost 60 years approved by US senate

By Niklas Mattsson | Posted on March 11, 2011

Most comprehensive patent reform in almost 60 years approved by US senate Historic breakthrough as USA gets to grips with “first-to-invent”, the enormous backlog of patent applications and simplifying procedures for filing patents in the USA. On Tuesday 8 March 2011, the US Senate voted to approve the nation’s most comprehensive patent reform since 1952,...

Tags: Patent, Reform, USA

Controversial gene patents finally decided by the EPO

By Niklas Mattsson | Posted on November 27, 2008

During the last decade, the debate in Europe regarding the patentability of human gene inventions has been heavily influenced by “the Myriad case”, concerning patent applications by Myriad Genetics Inc (and others) that relate to the breast cancer susceptibility genes BRCA1 and BRCA2. Through two decisions spaced less than a week apart, the European Patent...

Tags: EPO, gene patents

USPTO will not give up

By Niklas Mattsson | Posted on June 10, 2008

Last fall, the US Patent and Trademark Office, USPTO, announced that they would make drastic changes in the rules concerning patent applications. Briefly, the USPTO rules mean that the applicant’s rights to file different forms of continuation applications are severely limited. The rules were meant to become effective on 1 November 2007. Tons of companies...

Tags: USPTO

Recent contributors

Laura Stravinskaite

Laura Stravinskaite

Senior Associate, Attorney at Law

Ai-Leen Lim

Ai-Leen Lim

Partner, Attorney at Law, Group Vice President

Ashley Zhao

Ashley Zhao

Partner, Attorney at Law, Business Area Manager

Troels Peter Rørdam

Troels Peter Rørdam

Senior Counsel, European Patent Attorney

Mikkel Roed Trier

Mikkel Roed Trier

Partner, European Patent Attorney, UPC Representative, Business Area Manager